Glenmark Pharmaceuticals share news, announcements and annual reports
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Glenmark Pharmaceuticals Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000
Last close ₹2,382.00up ₹83.30 (3.62%)BSE ₹2,388.00
Share price at the NSE close on 2 Nov 2026. Previous close ₹2,298.70.
2 Nov: open ₹2,306.00, high ₹2,400.10, low ₹2,306.00
52-week range of traded prices to 2 Nov 2026
₹1,801.40Low, 7 Nov 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹67,226 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 37.39
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 17.97
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 6.40
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.11%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 15,49,67347.5% delivered
Glenmark Pharmaceuticals share news and announcements
1,381 announcements, routine notices left out, newest first. Page 25 of 28.
Aug 2009
10 Aug · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated August 10, 2009, titled "Crofelemer dose selection stage of Phase III trials completed. Molecule progresses to final stage of Phase III trials in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.7 Aug · Limited Review Report
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter ended June 30,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Aug · Meeting
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the Notice of Postal Ballot Pursuant to Section 192A(2) of the Companies Act, 1956. A copy of the notice of postal ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
31 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 31, 2009, titled "Glenmark Generics receives ANDA approval from the U.S. FDA for Alclometasone Dipropionate Ointment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jul · Raising of Funds/Others
Glenmark Pharmaceuticals Ltd. has informed the Exchange that at the Meeting of the Board of Directors held on July 27, 2009, the Board has: 1) approved raising of funds through issue of Equity Shares / GDRs / ADRs / FCCBs and/or such other securities for an amount not exceeding US $ 250 million either through preferential issue and/or qualified institutional placement and / or private placement etc. subject to the approval of shareholders. 2) converted 84,000 stock options issued to its employees into 84,000 Equity Shares pursuant to the ESOS 2003.27 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 27, 2009, titled "Glenmark's Consolidated revenue increases by 18% to Rs. 5,436.88 million for Q1-FY'10. Consolidated Net Profit at Rs 534.55 million for the quarter". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the First quarter ended June 30, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 54368.76 lacs for quarter ending on 30-JUN-2009 against Rs. 46082.49 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 5345.46 lacs for the quarter ending on 30-JUN-2009 against Rs. 11537.68 lacs for the quarter ending on 30-JUN-2008.27 Jul · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 21995.92 lacs for quarter ending on 30-JUN-2009 against Rs. 19397.51 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 522 lacs for the quarter ending on 30-JUN-2009 against Rs. 5683.57 lacs for the quarter ending on 30-JUN-2008.21 Jul · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "At the Compensation Committee held on July 14, 2009 the Committee has issue 141,500 stock options to the permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re.1/- each in one or more tranches and Cancelled 224,000 stock options".17 Jul · Board meeting
To consider and approve the Un-Audited Financial Results for the First Quarter ended June 30, 2009.10 Jul · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated July 10, 2009, titled "Glenmark to launch Fosinopril Sodium and Hydrochlorothiazide tablets in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
27 Jun · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its Meeting held on June 26, 2009 allotted 25,800 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 200327 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 26, 2009, titled "Glenmark's Consolidated revenue increases by 6% to Rs. 21,215.39 Mn; Consolidated Net Profit was at 1934.73 million". The Company has further submitted to the Exchange a copy of the Management Discussion and Analysis for the Fourth quarter of the Financial Year 2008-09 Ended March 31, 2009. The copies of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jun · Dividend
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company at its Meeting held on June 26, 2009 has recommended dividend @ Re.0.40 (face value Rs.1/-) on the Equity Share Capital of the Company for the financial year 2008-2009 subject to the approval of the Shareholders at the Annual General Meeting.26 Jun · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 85529.13 lacs for year ending on 31-MAR-2009 against Rs. 137269.08 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 21792.63 lacs for the year ending on 31-MAR-2009 against Rs. 38902.38 lacs for the year ending on 31-MAR-2008.26 Jun · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 209301.68 lacs for year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 19347.29 lacs for the year ending on 31-MAR-2009.26 Jun · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 19115.59 lacs for quarter ending on 31-MAR-2009 against Rs. 39689.78 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 5728.44 lacs for the quarter ending on 31-MAR-2009 against Rs. 13014.09 lacs for the quarter ending on 31-MAR-2008.26 Jun · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 49108.33 lacs for quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. (12069.59) lacs for the quarter ending on 31-MAR-2009.25 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 25, 2009, titled "Glenmark Generics receives ANDA approval from the U.S. FDA for Alclometasone Dipropionate Cream". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 24, 2009 titled "Glenmark's novel molecule for Diabetes, Melogliptin to enter phase III trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Jun · Board meeting
1) To consider and approve the Company's audited financial statements for the year ended March 31, 2009. 2) To consider declaration of dividend on Equity Shares for the year ended March 31, 2009.1 Jun · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated June 01, 2009, titled "Glenmark receives ANDA approval from U.S. FDA for Hydralazine Hydrochloride Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.1 Jun · Conversion
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Operations Committee of the Company at its meeting held on 29th May, 2009 has converted 33,000 stock options issued to its employees into 33,000 Equity Shares pursuant to the ESOS 2003".
Apr 2009
27 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding press release informing that the Company's subsidiary has received tentative approval from US-FDA for cholesterol-lowering agent Ezetimibe. In this regard Company has submitted a copy of press release dated April 27, 2009, titled "Glenmark receives tentative approval from US-FDA for cholesterol-lowering agent Ezetimibe". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Apr · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Audited Financial Results of the Company for the financial year ended March 31, 2009 would be published on or before June 30, 2009. Hence, the Company would not be publishing the Un-Audited Financial Results for the last quarter ended March 31, 2009.17 Apr · Board meeting
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Board of Directors of the Company, at its Meeting held on April 17, 2009 allotted 7,000 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.15 Apr · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "In line with the requirements of Clause 49 I (A) of the listing agreement relating to the composition of the Board, the Board of Directors has been reconstituted. As part of the reconstitution, Mr. R. V. Desai Director-Finance & Legal and Mrs. B. E. Saldanha Director have resigned from the board effective April 01, 2009. Mr. R.V. Desai continues as CFO of the Company effective April 01, 2009".13 Apr · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated April 13, 2009, titled "Glenmark's molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
30 Mar · Updates
Glenmark Pharmaceuticals Ltd. has informed the Exchange that: "The Compensation Committee of the Company at its meeting held on 25th March 2009 has cancelled 667,000 stock options pursuant to the ESOS 2003".
Feb 2009
26 Feb · Management
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Mr. M. J. Mendonza, has joined the Company as Vice President-Legal & Company Secretary with effect from February 06, 2009.26 Feb · Change in Designation
Glenmark Pharmaceuticals Ltd. has informed the Exchange that Mr. Sanjay Chowdhary, Company Secretary will be re-designated as Joint Company Secretary and Compliance Officer w.e.f. February 06, 2009 of the Company.13 Feb · Issue of Stock Options
Glenmark Pharmaceuticals Ltd. has informed the Exchange that:"The Compensation Committee of the Company, at its meeting held on February 05, 2009 has issued 7,01,500 stock options to permanent employees pursuant to ESOS 2003. Each option shall be convertible into one equity share of Re. 1/- each in one or more tranches. Further, the Compensation Committee has cancelled 7,48,000 stock options pursuant to ESOS 2003."9 Feb · Disclosure
Glenmark Pharmaceuticals Ltd. has informed the Exchange that the Promoters / Promoter Group of the Company have not pledged any of their shares held in the Company. The report under Regulations 8A (4) shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Feb · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated February 04, 2009, titled "Glenmark receives approval from the U.S. FDA for Lithium Carbonate Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
27 Jan · Business
Glenmark Pharmaceuticals Ltd. has submitted to the Exchange a copy of the Management Discussion & Analysis for the 3rd quarter of the Financial Year 2008-09 ended December 31, 2008 and copy of press release dated January 27, 2009, titled "Glenmark's consolidated revenue at Rs.5813.89 mn, declines by 14.42%; Net Profit at Rs.814.32 mn, declines by 70.91% for Q3 FY09". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.27 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 24430.62 lacs for quarter ending on 31-DEC-2008 against Rs. 43357.92 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 3691.96 lacs for the quarter ending on 31-DEC-2008 against Rs. 14642.68 lacs for the quarter ending on 31-DEC-2007.27 Jan · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 58138.94 lacs for quarter ending on 31-DEC-2008 against Rs. 67939.11 lacs for the quarter ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 8143.19 lacs for the quarter ending on 31-DEC-2008 against Rs. 28001.88 lacs for the quarter ending on 31-DEC-2007.23 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 23, 2009, titled "Glenmark's molecule for Osteoarthritic and Neuropathic Pain, GRC 15300, to enter Phase I trials". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jan · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated January 16, 2009, titled "Glenmark to market Levetiracetam tablets for the US market. U.S. FDA grants Day 1 ANDA approval". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.9 Jan · Board meeting
Meeting on 27 Jan 2009: “Unaudited Financial Results for the qtr ended Dec 31, 2008”
Dec 2008
22 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 22, 2008, titled "Glenmark expects launch of Crofelemer in ROW Countries (Developing Economies) by 2010". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.18 Dec · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company, at its Operations Committee Meeting held today i.e on December 18, 2008 allotted 33,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003".17 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 17, 2008, titled "Glenmark Confirms Patent Challenge of Fluticasone Lotion". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.11 Dec · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated December 11, 2008, titled "SCRIP, the leading pharmaceutical magazine in the world Crowns Glenmark as the "Best Pharma Company in the World- SME" and the "Best Company in Emerging Markets" at the SCRIP Awards 2008 in London". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
24 Nov · Allotment of shares
Glenmark Pharmaceuticals Ltd. has informed the Exchange that "The Board of Directors of the Company, at its Operations Committee Meeting held today i.e on November 24, 2008 allotted 2,19,200 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003".21 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding a press release dated November 21, 2008, titled "Glenmark receives approval for Ranitidine Tablets USP from the U.S. FDA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the press release dated November 20, 2008, titled "Glenmark Launches Azathioprine Tablets in the U.S. Market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.10 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the press release dated November 10, 2008, titled "Glenmark Generics Ltd enhances Pain Management Portfolio for the U.S. Market; Launches Morphine Sulfate Oral Solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Nov · Business
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the press release dated November 06, 2008, titled "Glenmark Generics Limited launches its first product in the United Kingdom; Launches Perindopril, an ACE inhibitor for symptomatic heart failure". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
27 Oct · Results
Glenmark Pharmaceuticals Ltd. has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 102054.42 lacs for half year ending on 30-SEP-2008 against Rs. 72625.51 lacs for the half year ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 23273.69 lacs for the half year ending on 30-SEP-2008 against Rs. 13227.75 lacs for the half year ending on 30-SEP-2007.